{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:32:55Z","timestamp":1794432775806,"version":"4.9.1"},"reference-count":232,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41573-026-01509-0","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:19:37Z","timestamp":1787566777000},"page":"877-894","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Towards precision psychiatry: initial foundations and future directions"],"prefix":"10.1038","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8259-3521","authenticated-orcid":false,"given":"Amit","family":"Etkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7788-624X","authenticated-orcid":false,"given":"Patricio","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5158-1103","authenticated-orcid":false,"given":"Kerry J.","family":"Ressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1679-8749","authenticated-orcid":false,"given":"Husseini","family":"Manji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"1509_CR1","unstructured":"FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and Other Tools) Resource [online] https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK326791\/ (FDA, 2016)."},{"key":"1509_CR2","unstructured":"Rockoff, J. D. & Loftus, P. Bristol-Myers bucks trend toward precision medicine. Wall Street Journal https:\/\/www.wsj.com\/articles\/bristol-bucks-trend-toward-precision-medicine-1457912801 (13 Mar 2016)."},{"key":"1509_CR3","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s40263-025-01204-5","volume":"39","author":"A McGuigan","year":"2025","unstructured":"McGuigan, A. & Blair, H. A. Tofersen: a review in amyotrophic lateral sclerosis associated with SOD1 mutations. CNS Drugs 39, 903\u2013912 (2025).","journal-title":"CNS Drugs"},{"key":"1509_CR4","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512\u2013527 (2023).","journal-title":"JAMA"},{"key":"1509_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1509_CR6","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","volume":"20","author":"SE Schindler","year":"2024","unstructured":"Schindler, S. E. et al. Acceptable performance of blood biomarker tests of amyloid pathology \u2014 recommendations from the Global CEO Initiative on Alzheimer\u2019s Disease. Nat. Rev. Neurol. 20, 426\u2013439 (2024).","journal-title":"Nat. Rev. Neurol."},{"key":"1509_CR7","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1001\/jamapsychiatry.2024.2553","volume":"81","author":"A Etkin","year":"2024","unstructured":"Etkin, A. & Mathalon, D. H. Bringing imaging biomarkers into clinical reality in psychiatry. JAMA Psychiatry 81, 1142\u20131147 (2024).","journal-title":"JAMA Psychiatry"},{"key":"1509_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.euroneuro.2022.08.001","volume":"63","author":"P Fusar-Poli","year":"2022","unstructured":"Fusar-Poli, P. et al. Ethical considerations for precision psychiatry: a roadmap for research and clinical practice. Eur. Neuropsychopharmacol. 63, 17\u201334 (2022).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"1509_CR9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1126\/science.adg8538","volume":"383","author":"AM Chekroud","year":"2024","unstructured":"Chekroud, A. M. et al. Illusory generalizability of clinical prediction models. Science 383, 164\u2013167 (2024).","journal-title":"Science"},{"key":"1509_CR10","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1001\/jamapsychiatry.2018.0252","volume":"75","author":"DA Pizzagalli","year":"2018","unstructured":"Pizzagalli, D. A. et al. Pretreatment rostral anterior cingulate cortex theta activity in relation to symptom improvement in depression: a randomized clinical trial. JAMA Psychiatry 75, 547\u2013554 (2018).","journal-title":"JAMA Psychiatry"},{"key":"1509_CR11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/npp.2010.166","volume":"36","author":"DA Pizzagalli","year":"2011","unstructured":"Pizzagalli, D. A. Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology 36, 183\u2013206 (2011).","journal-title":"Neuropsychopharmacology"},{"key":"1509_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jpsychires.2021.06.021","volume":"141","author":"C-T Ip","year":"2021","unstructured":"Ip, C.-T. et al. NeuroPharm study: EEG wakefulness regulation as a biomarker in MDD. J. Psychiatr. Res. 141, 57\u201365 (2021).","journal-title":"J. Psychiatr. Res."},{"key":"1509_CR13","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s44220-023-00160-7","volume":"1","author":"HTS Voetterl","year":"2023","unstructured":"Voetterl, H. T. S. et al. Alpha peak frequency-based Brainmarker-I as a method to stratify to pharmacotherapy and brain stimulation treatments in depression. Nat. Ment. Health 1, 1023\u20131032 (2023).","journal-title":"Nat. Ment. Health"},{"key":"1509_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.euroneuro.2024.09.007","volume":"89","author":"H Voetterl","year":"2024","unstructured":"Voetterl, H. et al. Does 18 Hz deep TMS benefit a different subgroup of depressed patients relative to 10 Hz rTMS? The role of the individual alpha frequency. Eur. Neuropsychopharmacol. 89, 73\u201381 (2024).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"1509_CR15","first-page":"52","volume":"8","author":"H Voetterl","year":"2023","unstructured":"Voetterl, H. et al. Brainmarker-I differentially predicts remission to various attention-deficit\/hyperactivity disorder treatments: a discovery, transfer, and blinded validation study. Biol. Psychiatry Cogn. Neurosci. Neuroimaging 8, 52\u201360 (2023).","journal-title":"Biol. Psychiatry Cogn. Neurosci. Neuroimaging"},{"key":"1509_CR16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.36094","volume":"6","author":"B Schwartzmann","year":"2023","unstructured":"Schwartzmann, B. et al. Developing an electroencephalography-based model for predicting response to antidepressant medication. JAMA Netw. Open 6, e2336094 (2023).","journal-title":"JAMA Netw. Open"},{"key":"1509_CR17","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41587-019-0397-3","volume":"38","author":"W Wu","year":"2020","unstructured":"Wu, W. et al. An electroencephalographic signature predicts antidepressant response in major depression. Nat. Biotechnol. 38, 439\u2013447 (2020).","journal-title":"Nat. Biotechnol."},{"key":"1509_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-020-00614-8","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. Identification of psychiatric disorder subtypes from functional connectivity patterns in resting-state electroencephalography. Nat. Biomed. Eng. https:\/\/doi.org\/10.1038\/s41551-020-00614-8 (2020).","journal-title":"Nat. Biomed. Eng."},{"key":"1509_CR19","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s44220-023-00049-5","volume":"1","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y. et al. Machine learning-based identification of a psychotherapy-predictive electroencephalographic signature in PTSD. Nat. Ment. Health 1, 284\u2013294 (2023).","journal-title":"Nat. Ment. Health"},{"key":"1509_CR20","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1176\/appi.ajp.20220306","volume":"180","author":"IG Elbau","year":"2023","unstructured":"Elbau, I. G. et al. Functional connectivity mapping for rTMS target selection in depression. Am. J. Psychiatry 180, 230\u2013240 (2023).","journal-title":"Am. J. Psychiatry"},{"key":"1509_CR21","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/j.biopsych.2021.02.015","volume":"90","author":"SH Siddiqi","year":"2021","unstructured":"Siddiqi, S. H., Weigand, A., Pascual-Leone, A. & Fox, M. D. Identification of personalized transcranial magnetic stimulation targets based on subgenual cingulate connectivity: an independent replication. Biol. Psychiatry 90, e55\u2013e56 (2021).","journal-title":"Biol. Psychiatry"},{"key":"1509_CR22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.biopsych.2017.10.028","volume":"84","author":"A Weigand","year":"2018","unstructured":"Weigand, A. et al. Prospective validation that subgenual connectivity predicts antidepressant efficacy of transcranial magnetic stimulation sites. Biol. Psychiatry 84, 28\u201337 (2018).","journal-title":"Biol. Psychiatry"},{"key":"1509_CR23","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41586-024-07805-2","volume":"633","author":"CJ Lynch","year":"2024","unstructured":"Lynch, C. J. et al. Frontostriatal salience network expansion in individuals in depression. Nature 633, 624\u2013633 (2024).","journal-title":"Nature"},{"key":"1509_CR24","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2020.65","volume":"63","author":"C L\u00f3pez-Sol\u00e0","year":"2020","unstructured":"L\u00f3pez-Sol\u00e0, C. et al. Is cognitive dysfunction involved in difficult-to-treat depression? Characterizing resistance from a cognitive perspective. Eur. Psychiatry 63, e74 (2020).","journal-title":"Eur. Psychiatry"},{"key":"1509_CR25","doi-asserted-by":"publisher","first-page":"e1023","DOI":"10.4088\/JCP.14m09438","volume":"76","author":"MJ Nijdam","year":"2015","unstructured":"Nijdam, M. J., de Vries, G.-J., Gersons, B. P. R. & Olff, M. Response to psychotherapy for posttraumatic stress disorder: the role of pretreatment verbal memory performance. J. Clin. Psychiatry 76, e1023\u2013e1028 (2015).","journal-title":"J. Clin. Psychiatry"},{"key":"1509_CR26","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1176\/appi.ajp.20220785","volume":"180","author":"KM Deligiannidis","year":"2023","unstructured":"Deligiannidis, K. M. et al. Zuranolone for the treatment of postpartum depression. Am. J. Psychiatry 180, 668\u2013675 (2023).","journal-title":"Am. J. Psychiatry"},{"key":"1509_CR27","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1176\/appi.ajp.20220459","volume":"180","author":"AH Clayton","year":"2023","unstructured":"Clayton, A. H. et al. Zuranolone for the treatment of adults with major depressive disorder: a randomized, placebo-controlled phase 3 Trial. Am. J. Psychiatry 180, 676\u2013684 (2023).","journal-title":"Am. J. Psychiatry"},{"key":"1509_CR28","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/s41386-023-01751-9","volume":"49","author":"SV Parikh","year":"2024","unstructured":"Parikh, S. V. et al. Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study. Neuropsychopharmacology 49, 467\u2013475 (2024).","journal-title":"Neuropsychopharmacology"},{"key":"1509_CR29","doi-asserted-by":"publisher","first-page":"1332329","DOI":"10.3389\/fnins.2023.1332329","volume":"17","author":"S Wang","year":"2023","unstructured":"Wang, S. et al. Efficacy and safety of zuranolone in the treatment of major depressive disorder: a meta-analysis. Front. Neurosci. 17, 1332329 (2023).","journal-title":"Front. Neurosci."},{"key":"1509_CR30","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1007\/s11096-024-01714-0","volume":"46","author":"M Winslow","year":"2024","unstructured":"Winslow, M., White, E., Rose, S. J., Salzer, E. & Nemec, E. C. The efficacy of zuranolone versus placebo in postpartum depression and major depressive disorder: a systematic review and meta-analysis. Int. J. Clin. Pharm. 46, 590\u2013601 (2024).","journal-title":"Int. J. Clin. Pharm."},{"key":"1509_CR31","first-page":"106","volume":"18","author":"MM Batt","year":"2020","unstructured":"Batt, M. M., Duffy, K. A., Novick, A. M., Metcalf, C. A. & Epperson, C. N. Is postpartum depression different from depression occurring outside of the perinatal period? A review of the evidence. Focus (Am. Psychiatr. Publ.) 18, 106\u2013119 (2020).","journal-title":"Focus (Am. Psychiatr. Publ.)"},{"key":"1509_CR32","doi-asserted-by":"publisher","unstructured":"Luo, W. et al. Discovery of a potential novel pharmacogenomic biomarker on ANK3 gene for liafensine, a triple reuptake inhibitor for treatment-resistant depression. Transl. Psychiatry https:\/\/doi.org\/10.1038\/s41398-026-04144-w (2026).","DOI":"10.1038\/s41398-026-04144-w"},{"key":"1509_CR33","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1001\/jamapsychiatry.2025.2416","volume":"82","author":"G Wang","year":"2025","unstructured":"Wang, G. et al. ANK3 as a novel genetic biomarker for liafensine in treatment-resistant depression: the ENLIGHTEN randomized clinical trial. JAMA Psychiatry 82, 1186\u20131194 (2025).","journal-title":"JAMA Psychiatry"},{"key":"1509_CR34","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/ijnp\/pyab050","volume":"24","author":"A Savitz","year":"2021","unstructured":"Savitz, A. et al. Efficacy and safety of seltorexant as adjunctive therapy in major depressive disorder: a phase 2b, randomized, placebo-controlled, adaptive dose-finding study. Int. J. Neuropsychopharmacol. 24, 965\u2013976 (2021).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"1509_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-024-02846-5","author":"S Mesens","year":"2025","unstructured":"Mesens, S. et al. Treatment effect and safety of seltorexant as monotherapy for patients with major depressive disorder: a randomized, placebo-controlled clinical trial. Mol. Psychiatry https:\/\/doi.org\/10.1038\/s41380-024-02846-5 (2025).","journal-title":"Mol. Psychiatry"},{"key":"1509_CR36","unstructured":"Johnson & Johnson. Johnson & Johnson pivotal study of seltorexant shows statistically significant and clinically meaningful improvement in depressive symptoms and sleep disturbance outcomes. PR Newswire https:\/\/www.prnewswire.com\/news-releases\/johnson--johnson-pivotal-study-of-seltorexant-shows-statistically-significant-and-clinically-meaningful-improvement-in-depressive-symptoms-and-sleep-disturbance-outcomes-302157980.html (2024)."},{"key":"1509_CR37","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04533529 (2025)."},{"key":"1509_CR38","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/acps.13062","volume":"140","author":"TP Hui","year":"2019","unstructured":"Hui, T. P. et al. A systematic review and meta-analysis of clinical predictors of lithium response in bipolar disorder. Acta Psychiatr. Scand. 140, 94\u2013115 (2019).","journal-title":"Acta Psychiatr. Scand."},{"key":"1509_CR39","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1046\/j.1440-1819.2003.01112.x","volume":"57","author":"A Ikeda","year":"2003","unstructured":"Ikeda, A. & Kato, T. Biological predictors of lithium response in bipolar disorder. Psychiatry Clin. Neurosci. 57, 243\u2013250 (2003).","journal-title":"Psychiatry Clin. Neurosci."},{"key":"1509_CR40","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I","volume":"6","author":"TF Freund","year":"1996","unstructured":"Freund, T. F. & Buzs\u00e1ki, G. Interneurons of the hippocampus. Hippocampus 6, 347\u2013470 (1996).","journal-title":"Hippocampus"},{"key":"1509_CR41","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.euroneuro.2024.02.010","volume":"82","author":"O Mar\u00edn","year":"2024","unstructured":"Mar\u00edn, O. Parvalbumin interneuron deficits in schizophrenia. Eur. Neuropsychopharmacol. 82, 44\u201352 (2024).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"1509_CR42","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1093\/schbul\/sbs010","volume":"38","author":"G Gonzalez-Burgos","year":"2012","unstructured":"Gonzalez-Burgos, G. & Lewis, D. A. NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia. Schizophr. Bull. 38, 950\u2013957 (2012).","journal-title":"Schizophr. Bull."},{"key":"1509_CR43","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/nrn1648","volume":"6","author":"DA Lewis","year":"2005","unstructured":"Lewis, D. A., Hashimoto, T. & Volk, D. W. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 6, 312\u2013324 (2005).","journal-title":"Nat. Rev. Neurosci."},{"key":"1509_CR44","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/mp.2017.47","volume":"22","author":"P Steullet","year":"2017","unstructured":"Steullet, P. et al. Oxidative stress-driven parvalbumin interneuron impairment as a common mechanism in models of schizophrenia. Mol. Psychiatry 22, 936\u2013943 (2017).","journal-title":"Mol. Psychiatry"},{"key":"1509_CR45","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S0165-0173(99)00042-9","volume":"31","author":"DA Lewis","year":"2000","unstructured":"Lewis, D. A. GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia. Brain Res. Rev. 31, 270\u2013276 (2000).","journal-title":"Brain Res. Rev."},{"key":"1509_CR46","doi-asserted-by":"publisher","first-page":"102509","DOI":"10.1016\/j.arr.2024.102509","volume":"101","author":"CL Smeralda","year":"2024","unstructured":"Smeralda, C. L. et al. The role of parvalbumin interneuron dysfunction across neurodegenerative dementias. Ageing Res. Rev. 101, 102509 (2024).","journal-title":"Ageing Res. Rev."},{"key":"1509_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.25391","volume":"102","author":"Y Yao","year":"2024","unstructured":"Yao, Y. & Li, Q. The role of parvalbumin interneurons in autism spectrum disorder. J. Neurosci. Res. 102, e25391 (2024).","journal-title":"J. Neurosci. Res."},{"key":"1509_CR48","doi-asserted-by":"publisher","first-page":"17642","DOI":"10.1073\/pnas.1409271111","volume":"111","author":"DJ Cahalane","year":"2014","unstructured":"Cahalane, D. J., Charvet, C. J. & Finlay, B. L. Modeling local and cross-species neuron number variations in the cerebral cortex as arising from a common mechanism. Proc. Natl Acad. Sci. USA 111, 17642\u201317647 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1509_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2004.12.002","volume":"76","author":"D Umbricht","year":"2005","unstructured":"Umbricht, D. & Krljes, S. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr. Res. 76, 1\u201323 (2005).","journal-title":"Schizophr. Res."},{"key":"1509_CR50","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.neuron.2014.07.028","volume":"83","author":"J-H Cabungcal","year":"2014","unstructured":"Cabungcal, J.-H. et al. Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia. Neuron 83, 1073\u20131084 (2014).","journal-title":"Neuron"},{"key":"1509_CR51","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/35004582","volume":"404","author":"M Fagiolini","year":"2000","unstructured":"Fagiolini, M. & Hensch, T. K. Inhibitory threshold for critical-period activation in primary visual cortex. Nature 404, 183\u2013186 (2000).","journal-title":"Nature"},{"key":"1509_CR52","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1111\/j.1460-9568.2012.08130.x","volume":"35","author":"P O\u2019Donnell","year":"2012","unstructured":"O\u2019Donnell, P. Cortical interneurons, immune factors and oxidative stress as early targets for schizophrenia. Eur. J. Neurosci. 35, 1866\u20131870 (2012).","journal-title":"Eur. J. Neurosci."},{"key":"1509_CR53","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.schres.2014.06.021","volume":"176","author":"P Steullet","year":"2016","unstructured":"Steullet, P. et al. Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: a \u201ccentral hub\u201d in schizophrenia pathophysiology? Schizophr. Res. 176, 41\u201351 (2016).","journal-title":"Schizophr. Res."},{"key":"1509_CR54","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/schbul\/sbr056","volume":"37","author":"LV Moran","year":"2011","unstructured":"Moran, L. V. & Hong, L. E. High vs low frequency neural oscillations in schizophrenia. Schizophr. Bull. 37, 659\u2013663 (2011).","journal-title":"Schizophr. Bull."},{"key":"1509_CR55","unstructured":"Spencer, K. M. in Neurophysiologic Biomarkers in Neuropsychiatric Disorders: Etiologic and Treatment Considerations (eds Javitt, D. C. & McPartland, J. C.) 321\u2013349 (Springer, 2024)."},{"key":"1509_CR56","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/npp.2009.168","volume":"35","author":"LE Hong","year":"2010","unstructured":"Hong, L. E. et al. Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine. Neuropsychopharmacology 35, 632\u2013640 (2010).","journal-title":"Neuropsychopharmacology"},{"key":"1509_CR57","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1016\/j.clinph.2012.03.011","volume":"123","author":"LE Hong","year":"2012","unstructured":"Hong, L. E., Moran, L. V., Du, X., O\u2019Donnell, P. & Summerfelt, A. Mismatch negativity and low frequency oscillations in schizophrenia families. Clin. Neurophysiol. 123, 1980\u20131988 (2012).","journal-title":"Clin. Neurophysiol."},{"key":"1509_CR58","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/s41386-023-01560-0","volume":"48","author":"P O\u2019Donnell","year":"2023","unstructured":"O\u2019Donnell, P. et al. The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial. Neuropsychopharmacology 48, 1052\u20131059 (2023).","journal-title":"Neuropsychopharmacology"},{"key":"1509_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2026.03.1008","author":"M Cecchi","year":"2026","unstructured":"Cecchi, M. et al. Baseline mismatch negativity amplitude predicts direction and magnitude of ketamine effect in healthy volunteers: a disordinal effect. Biol. Psychiatry https:\/\/doi.org\/10.1016\/j.biopsych.2026.03.1008 (2026).","journal-title":"Biol. Psychiatry"},{"key":"1509_CR60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0301406","volume":"19","author":"FG \u00d8stergaard","year":"2024","unstructured":"\u00d8stergaard, F. G. et al. The aperiodic exponent of neural activity varies with vigilance state in mice and men. PLoS ONE 19, e0301406 (2024).","journal-title":"PLoS ONE"},{"key":"1509_CR61","doi-asserted-by":"publisher","first-page":"149052","DOI":"10.1016\/j.brainres.2024.149052","volume":"1840","author":"RJ Earl","year":"2024","unstructured":"Earl, R. J., Ford, T. C., Lum, J. A. G., Enticott, P. G. & Hill, A. T. Exploring aperiodic activity in first episode schizophrenia spectrum psychosis: a resting-state EEG analysis. Brain Res. 1840, 149052 (2024).","journal-title":"Brain Res."},{"key":"1509_CR62","doi-asserted-by":"publisher","first-page":"101373","DOI":"10.1016\/j.dcn.2024.101373","volume":"66","author":"SD McKeon","year":"2024","unstructured":"McKeon, S. D. et al. Aperiodic EEG and 7T MRSI evidence for maturation of E\/I balance supporting the development of working memory through adolescence. Dev. Cogn. Neurosci. 66, 101373 (2024).","journal-title":"Dev. Cogn. Neurosci."},{"key":"1509_CR63","doi-asserted-by":"publisher","first-page":"7144","DOI":"10.1523\/JNEUROSCI.0414-22.2022","volume":"42","author":"M Gyurkovics","year":"2022","unstructured":"Gyurkovics, M., Clements, G. M., Low, K. A., Fabiani, M. & Gratton, G. Stimulus-induced changes in 1\/f-like background activity in EEG. J. Neurosci. 42, 7144\u20137151 (2022).","journal-title":"J. Neurosci."},{"key":"1509_CR64","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/s41380-021-01313-9","volume":"27","author":"I Khadimallah","year":"2022","unstructured":"Khadimallah, I. et al. Mitochondrial, exosomal miR137-COX6A2 and gamma synchrony as biomarkers of parvalbumin interneurons, psychopathology, and neurocognition in schizophrenia. Mol. Psychiatry 27, 1192\u20131204 (2022).","journal-title":"Mol. Psychiatry"},{"key":"1509_CR65","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1001\/jamapsychiatry.2024.0785","volume":"81","author":"I Kaul","year":"2024","unstructured":"Kaul, I. et al. Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial. JAMA Psychiatry 81, 749\u2013756 (2024).","journal-title":"JAMA Psychiatry"},{"key":"1509_CR66","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1176\/appi.ajp.20240076","volume":"182","author":"WP Horan","year":"2024","unstructured":"Horan, W. P. et al. The impact of xanomeline and trospium chloride on cognitive impairment in acute schizophrenia: replication in pooled data from two phase 3 trials. Am. J. Psychiatry 182, 297\u2013306 (2024).","journal-title":"Am. J. Psychiatry"},{"key":"1509_CR67","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3389\/fpsyt.2019.00648","volume":"10","author":"J Cotter","year":"2019","unstructured":"Cotter, J., Barnett, J. H. & Granger, K. The use of cognitive screening in pharmacotherapy trials for cognitive impairment associated with schizophrenia. Front. Psychiatry 10, 648 (2019).","journal-title":"Front. Psychiatry"},{"key":"1509_CR68","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1038\/npp.2015.176","volume":"40","author":"RS Keefe","year":"2015","unstructured":"Keefe, R. S. et al. Randomized, double-blind, placebo-controlled study of encenicline, an \u03b17 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia. Neuropsychopharmacology 40, 3053\u20133060 (2015).","journal-title":"Neuropsychopharmacology"},{"key":"1509_CR69","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.biopsych.2015.03.016","volume":"78","author":"BJ Kinon","year":"2015","unstructured":"Kinon, B. J., Millen, B. A., Zhang, L. & McKinzie, D. L. Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2\/3 receptor agonist pomaglumetad methionil in schizophrenia. Biol. Psychiatry 78, 754\u2013762 (2015).","journal-title":"Biol. Psychiatry"},{"key":"1509_CR70","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1038\/s41386-020-0706-z","volume":"45","author":"JT Kantrowitz","year":"2020","unstructured":"Kantrowitz, J. T. et al. Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers. Neuropsychopharmacology 45, 1842\u20131850 (2020).","journal-title":"Neuropsychopharmacology"},{"key":"1509_CR71","doi-asserted-by":"publisher","first-page":"pyae066","DOI":"10.1093\/ijnp\/pyae066","volume":"28","author":"RT Terry-Lorenzo","year":"2025","unstructured":"Terry-Lorenzo, R. T., Fan, R. H., Khin, N. A. & Singh, J. B. Therapeutic potential of D-amino acid oxidase inhibitors for cognitive impairment associated with schizophrenia: learnings from luvadaxistat. Int. J. Neuropsychopharmacol. 28, pyae066 (2025).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"1509_CR72","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s00406-023-01576-z","volume":"273","author":"H Rosenbrock","year":"2023","unstructured":"Rosenbrock, H., Desch, M. & Wunderlich, G. Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 273, 1557\u20131566 (2023).","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"1509_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-02096-5","volume":"12","author":"C Schultheis","year":"2022","unstructured":"Schultheis, C. et al. Quantitative electroencephalography parameters as neurophysiological biomarkers of schizophrenia-related deficits: a Phase II substudy of patients treated with iclepertin (BI 425809). Transl. Psychiatry 12, 329 (2022).","journal-title":"Transl. Psychiatry"},{"key":"1509_CR74","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.schres.2024.06.017","volume":"270","author":"V Murthy","year":"2024","unstructured":"Murthy, V. et al. INTERACT: a randomized phase 2 study of the DAAO inhibitor luvadaxistat in adults with schizophrenia. Schizophr. Res. 270, 249\u2013257 (2024).","journal-title":"Schizophr. Res."},{"key":"1509_CR75","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.schres.2013.08.020","volume":"150","author":"VL Stauffer","year":"2013","unstructured":"Stauffer, V. L. et al. Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo. Schizophr. Res. 150, 434\u2013441 (2013).","journal-title":"Schizophr. Res."},{"key":"1509_CR76","doi-asserted-by":"publisher","first-page":"116298","DOI":"10.1016\/j.bcp.2024.116298","volume":"228","author":"DL Uliana","year":"2024","unstructured":"Uliana, D. L., Lisboa, J. R. F., Gomes, F. V. & Grace, A. A. The excitatory-inhibitory balance as a target for the development of novel drugs to treat schizophrenia. Biochem. Pharmacol. 228, 116298 (2024).","journal-title":"Biochem. Pharmacol."},{"key":"1509_CR77","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/0269881120946300","volume":"35","author":"J Gilleen","year":"2021","unstructured":"Gilleen, J. et al. The effects of roflumilast, a phosphodiesterase type-4 inhibitor, on EEG biomarkers in schizophrenia: a randomised controlled trial. J. Psychopharmacol. 35, 15\u201322 (2021).","journal-title":"J. Psychopharmacol."},{"key":"1509_CR78","doi-asserted-by":"publisher","first-page":"S279","DOI":"10.1016\/j.biopsych.2024.02.936","volume":"95","author":"AS Ravindran","year":"2024","unstructured":"Ravindran, A. S. et al. 437. Identification of brain\/behavior-based pro-cognitive pharmacodynamic effects for ALTO-101 in healthy volunteers: results from a randomized, double-blind phase 1 study. Biol. Psychiatry 95, S279 (2024).","journal-title":"Biol. Psychiatry"},{"key":"1509_CR79","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.schres.2017.07.008","volume":"191","author":"C Retsa","year":"2018","unstructured":"Retsa, C. et al. Treatment in early psychosis with N-acetyl-cysteine for 6 months improves low-level auditory processing: pilot study. Schizophr. Res. 191, 80\u201386 (2018).","journal-title":"Schizophr. Res."},{"key":"1509_CR80","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1001\/jamapsychiatry.2018.4600","volume":"76","author":"RP Auerbach","year":"2019","unstructured":"Auerbach, R. P., Pagliaccio, D. & Pizzagalli, D. A. Toward an improved understanding of anhedonia. JAMA Psychiatry 76, 571\u2013573 (2019).","journal-title":"JAMA Psychiatry"},{"key":"1509_CR81","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41583-018-0029-9","volume":"19","author":"M Husain","year":"2018","unstructured":"Husain, M. & Roiser, J. P. Neuroscience of apathy and anhedonia: a transdiagnostic approach. Nat. Rev. Neurosci. 19, 470\u2013484 (2018).","journal-title":"Nat. Rev. Neurosci."},{"key":"1509_CR82","doi-asserted-by":"publisher","first-page":"104578","DOI":"10.1016\/j.neubiorev.2022.104578","volume":"136","author":"CA Kelly","year":"2022","unstructured":"Kelly, C. A., Freeman, K. B. & Schumacher, J. A. Treatment-resistant depression with anhedonia: integrating clinical and preclinical approaches to investigate distinct phenotypes. Neurosci. Biobehav. Rev. 136, 104578 (2022).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"1509_CR83","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1176\/appi.ajp.20220423","volume":"179","author":"DA Pizzagalli","year":"2022","unstructured":"Pizzagalli, D. A. Toward a better understanding of the mechanisms and pathophysiology of anhedonia: are we ready for translation? Am. J. Psychiatry 179, 458\u2013469 (2022).","journal-title":"Am. J. Psychiatry"},{"key":"1509_CR84","doi-asserted-by":"publisher","first-page":"401","DOI":"10.9758\/cpn.23.1086","volume":"21","author":"A Serretti","year":"2023","unstructured":"Serretti, A. Anhedonia and depressive disorders. Clin. Psychopharmacol. Neurosci. 21, 401\u2013409 (2023).","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"1509_CR85","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/09637214211051363","volume":"31","author":"BN Cuthbert","year":"2022","unstructured":"Cuthbert, B. N. Research Domain Criteria (RDoC): progress and potential. Curr. Dir. Psychol. Sci. 31, 107\u2013114 (2022).","journal-title":"Curr. Dir. Psychol. Sci."},{"key":"1509_CR86","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/cns.12854","volume":"24","author":"C Lambert","year":"2018","unstructured":"Lambert, C. et al. Anhedonia in depression and schizophrenia: a transdiagnostic challenge. CNS Neurosci. Ther. 24, 615\u2013623 (2018).","journal-title":"CNS Neurosci. Ther."},{"key":"1509_CR87","doi-asserted-by":"crossref","unstructured":"Whitton, A. E. & Pizzagalli, D. A. in Anhedonia: Preclinical, Translational, and Clinical Integration. Current Topics in Behavioral Neurosciences, Vol. 58 (ed. Pizzagalli, D. A.) 111\u2013127 (Springer, 2022).","DOI":"10.1007\/7854_2022_323"},{"key":"1509_CR88","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nrn3381","volume":"14","author":"SJ Russo","year":"2013","unstructured":"Russo, S. J. & Nestler, E. J. The brain reward circuitry in mood disorders. Nat. Rev. Neurosci. 14, 609\u2013625 (2013).","journal-title":"Nat. Rev. Neurosci."},{"key":"1509_CR89","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/dneu.22446","volume":"77","author":"L Oikonomidis","year":"2017","unstructured":"Oikonomidis, L. et al. A dimensional approach to modeling symptoms of neuropsychiatric disorders in the marmoset monkey. Dev. Neurobiol. 77, 328\u2013353 (2017).","journal-title":"Dev. Neurobiol."},{"key":"1509_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01522-4","volume":"11","author":"X Zhu","year":"2021","unstructured":"Zhu, X. et al. Phenotypic and genetic associations between anhedonia and brain structure in UK Biobank. Transl. Psychiatry 11, 395 (2021).","journal-title":"Transl. Psychiatry"},{"key":"1509_CR91","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41386-021-01101-7","volume":"47","author":"DA Pizzagalli","year":"2022","unstructured":"Pizzagalli, D. A. & Roberts, A. C. Prefrontal cortex and depression. Neuropsychopharmacology 47, 225\u2013246 (2022).","journal-title":"Neuropsychopharmacology"},{"key":"1509_CR92","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.pnpbp.2019.01.002","volume":"92","author":"B Cao","year":"2019","unstructured":"Cao, B. et al. Pharmacological interventions targeting anhedonia in patients with major depressive disorder: a systematic review. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 92, 109\u2013117 (2019).","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"1509_CR93","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/1520-6394(2000)12:1+<2::AID-DA2>3.0.CO;2-4","volume":"12","author":"KJ Ressler","year":"2000","unstructured":"Ressler, K. J. & Nemeroff, C. B. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress. Anxiety 12, 2\u201319 (2000).","journal-title":"Depress. Anxiety"},{"key":"1509_CR94","doi-asserted-by":"crossref","unstructured":"Klein, M. E., Grice, A. B., Sheth, S., Go, M. & Murrough, J. W. in Anhedonia: Preclinical, Translational, and Clinical Integration. Current Topics in Behavioral Neurosciences, Vol. 58 (ed. Pizzagalli, D. A.) 489\u2013467 (Springer, 2022).","DOI":"10.1007\/7854_2022_357"},{"key":"1509_CR95","doi-asserted-by":"publisher","first-page":"pyae055","DOI":"10.1093\/ijnp\/pyae055","volume":"27","author":"A Luca","year":"2024","unstructured":"Luca, A. et al. Anhedonia is associated with a specific depression profile and poor antidepressant response. Int. J. Neuropsychopharmacol. 27, pyae055 (2024).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"1509_CR96","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/npp.2012.140","volume":"38","author":"F Chenu","year":"2013","unstructured":"Chenu, F., El Mansari, M. & Blier, P. Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine, and serotonin systems in the rat brain. Neuropsychopharmacology 38, 275\u2013284 (2013).","journal-title":"Neuropsychopharmacology"},{"key":"1509_CR97","doi-asserted-by":"publisher","first-page":"S505","DOI":"10.1016\/j.euroneuro.2012.07.004","volume":"22","author":"M Di Giannantonio","year":"2012","unstructured":"Di Giannantonio, M. & Martinotti, G. Anhedonia and major depression: the role of agomelatine. Eur. Neuropsychopharmacol. 22, S505\u2013S510 (2012).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"1509_CR98","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.biopsych.2020.04.009","volume":"88","author":"Y-S Ang","year":"2020","unstructured":"Ang, Y.-S. et al. Pretreatment reward sensitivity and frontostriatal resting-state functional connectivity are associated with response to bupropion after sertraline nonresponse. Biol. Psychiatry 88, 657\u2013667 (2020).","journal-title":"Biol. Psychiatry"},{"key":"1509_CR99","doi-asserted-by":"publisher","first-page":"104729","DOI":"10.1016\/j.nsa.2024.104729","volume":"3","author":"N Cooper","year":"2024","unstructured":"Cooper, N. et al. Effects of a novel histamine 3 receptor (H3R) on positive emotion and reward processing: methods and preliminary data in an ongoing phase 2 proof-of-concept study. Neurosci. Appl. 3, 104729 (2024).","journal-title":"Neurosci. Appl."},{"key":"1509_CR100","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jpsychires.2024.06.051","volume":"177","author":"RS Gupta","year":"2024","unstructured":"Gupta, R. S., Light, G. A., Simmons, A. N., Harl\u00e9, K. M. & Stout, D. M. Sex moderates the effect of anhedonia on parietal alpha asymmetry. J. Psychiatr. Res. 177, 97\u2013101 (2024).","journal-title":"J. Psychiatr. Res."},{"key":"1509_CR101","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jpsychires.2021.07.003","volume":"141","author":"A Umemoto","year":"2021","unstructured":"Umemoto, A. et al. Resting posterior alpha power and adolescent major depressive disorder. J. Psychiatr. Res. 141, 233\u2013240 (2021).","journal-title":"J. Psychiatr. Res."},{"key":"1509_CR102","unstructured":"US FDA. Letter regarding intent to market https:\/\/www.Accessdata.Fda.Gov\/Cdrh_docs\/Pdf22\/K222101.Pdf (2023)."},{"key":"1509_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2023.120183","volume":"276","author":"N Singer","year":"2023","unstructured":"Singer, N. et al. Development and validation of an fMRI-informed EEG model of reward-related ventral striatum activation. NeuroImage 276, 120183 (2023).","journal-title":"NeuroImage"},{"key":"1509_CR104","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1093\/brain\/awaa002","volume":"143","author":"AE Whitton","year":"2020","unstructured":"Whitton, A. E. et al. Baseline reward processing and ventrostriatal dopamine function are associated with pramipexole response in depression. Brain 143, 701\u2013710 (2020).","journal-title":"Brain"},{"key":"1509_CR105","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S0193-953X(05)70015-0","volume":"21","author":"AH Miller","year":"1998","unstructured":"Miller, A. H. Neuroendocrine and immune system interactions in stress and depression. Psychiatr. Clin. N. Am. 21, 443\u2013463 (1998).","journal-title":"Psychiatr. Clin. N. Am."},{"key":"1509_CR106","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.it.2005.11.006","volume":"27","author":"CL Raison","year":"2006","unstructured":"Raison, C. L., Capuron, L. & Miller, A. H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 27, 24\u201331 (2006).","journal-title":"Trends Immunol."},{"key":"1509_CR107","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/mp.2015.168","volume":"21","author":"JC Felger","year":"2016","unstructured":"Felger, J. C. et al. Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression. Mol. Psychiatry 21, 1358\u20131365 (2016).","journal-title":"Mol. Psychiatry"},{"key":"1509_CR108","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.bbi.2017.06.014","volume":"66","author":"Y Sun","year":"2017","unstructured":"Sun, Y. et al. The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman\u2019s disease. Brain Behav. Immun. 66, 156\u2013164 (2017).","journal-title":"Brain Behav. Immun."},{"key":"1509_CR109","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1038\/s41380-022-01715-3","volume":"27","author":"M Bekhbat","year":"2022","unstructured":"Bekhbat, M. et al. Functional connectivity in reward circuitry and symptoms of anhedonia as therapeutic targets in depression with high inflammation: evidence from a dopamine challenge study. Mol. Psychiatry 27, 4113\u20134121 (2022).","journal-title":"Mol. Psychiatry"},{"key":"1509_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01668-1","volume":"11","author":"S Costi","year":"2021","unstructured":"Costi, S. et al. Peripheral immune cell reactivity and neural response to reward in patients with depression and anhedonia. Transl. Psychiatry 11, 565 (2021).","journal-title":"Transl. Psychiatry"},{"key":"1509_CR111","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41573-021-00368-1","volume":"21","author":"WC Drevets","year":"2022","unstructured":"Drevets, W. C., Wittenberg, G. M., Bullmore, E. T. & Manji, H. K. Immune targets for therapeutic development in depression: towards precision medicine. Nat. Rev. Drug Discov. 21, 224\u2013244 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1509_CR112","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1177\/2045125318791944","volume":"8","author":"Y Lee","year":"2018","unstructured":"Lee, Y. et al. Anti-cytokine agents for anhedonia: targeting inflammation and the immune system to treat dimensional disturbances in depression. Ther. Adv. Psychopharmacol. 8, 337\u2013348 (2018).","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"1509_CR113","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1124\/pharmrev.120.000043","volume":"73","author":"MJ Lucido","year":"2021","unstructured":"Lucido, M. J. et al. Aiding and abetting anhedonia: impact of inflammation on the brain and pharmacological implications. Pharmacol. Rev. 73, 1084\u20131117 (2021).","journal-title":"Pharmacol. Rev."},{"key":"1509_CR114","doi-asserted-by":"publisher","first-page":"193","DOI":"10.12788\/acp.0034","volume":"33","author":"D Nogo","year":"2021","unstructured":"Nogo, D. et al. Examining the association between inflammation and motivational anhedonia in neuropsychiatric disorders: a systematic review. Ann. Clin. Psychiatry 33, 193\u2013206 (2021).","journal-title":"Ann. Clin. Psychiatry"},{"key":"1509_CR115","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/s41380-024-02751-x","volume":"30","author":"MT Treadway","year":"2024","unstructured":"Treadway, M. T. et al. A randomized proof-of-mechanism trial of TNF antagonism for motivational deficits and related corticostriatal circuitry in depressed patients with high inflammation. Mol. Psychiatry 30, 1407\u20131417\u00a0(2024).","journal-title":"Mol. Psychiatry"},{"key":"1509_CR116","doi-asserted-by":"publisher","first-page":"23nr15243","DOI":"10.4088\/JCP.23nr15243","volume":"85","author":"MM Rizk","year":"2024","unstructured":"Rizk, M. M. et al. Immune-targeted therapies for depression: current evidence for antidepressant effects of monoclonal antibodies. J. Clin. Psychiatry 85, 23nr15243 (2024).","journal-title":"J. Clin. Psychiatry"},{"key":"1509_CR117","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2014.105","volume":"4","author":"N Lally","year":"2014","unstructured":"Lally, N. et al. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl. Psychiatry 4, e469 (2014).","journal-title":"Transl. Psychiatry"},{"key":"1509_CR118","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1177\/0269881114568041","volume":"29","author":"N Lally","year":"2015","unstructured":"Lally, N. et al. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. J. Psychopharmacol. 29, 596\u2013607 (2015).","journal-title":"J. Psychopharmacol."},{"key":"1509_CR119","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1007\/s00213-022-06105-9","volume":"239","author":"D Nogo","year":"2022","unstructured":"Nogo, D. et al. The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits. Psychopharmacology 239, 2011\u20132039 (2022).","journal-title":"Psychopharmacology"},{"key":"1509_CR120","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.jad.2020.07.083","volume":"276","author":"NB Rodrigues","year":"2020","unstructured":"Rodrigues, N. B. et al. Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: results from the Canadian Rapid Treatment Center of Excellence. J. Affect. Disord. 276, 570\u2013575 (2020).","journal-title":"J. Affect. Disord."},{"key":"1509_CR121","doi-asserted-by":"publisher","first-page":"5096","DOI":"10.1038\/s41380-022-01757-7","volume":"27","author":"RB Price","year":"2022","unstructured":"Price, R. B. et al. International pooled patient-level meta-analysis of ketamine infusion for depression: in search of clinical moderators. Mol. Psychiatry 27, 5096\u20135112 (2022).","journal-title":"Mol. Psychiatry"},{"key":"1509_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109299","volume":"223","author":"MY Jawad","year":"2023","unstructured":"Jawad, M. Y. et al. The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression. Neuropharmacology 223, 109299 (2023).","journal-title":"Neuropharmacology"},{"key":"1509_CR123","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature10130","volume":"475","author":"AE Autry","year":"2011","unstructured":"Autry, A. E. et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475, 91\u201395 (2011).","journal-title":"Nature"},{"key":"1509_CR124","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1126\/science.1190287","volume":"329","author":"N Li","year":"2010","unstructured":"Li, N. et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959\u2013964 (2010).","journal-title":"Science"},{"key":"1509_CR125","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s40263-024-01114-y","volume":"38","author":"RS McIntyre","year":"2024","unstructured":"McIntyre, R. S. & Jain, R. Glutamatergic modulators for major depression from theory to clinical use. CNS Drugs 38, 869\u2013890 (2024).","journal-title":"CNS Drugs"},{"key":"1509_CR126","doi-asserted-by":"publisher","first-page":"1123797","DOI":"10.3389\/fnins.2023.1123797","volume":"17","author":"H Liu","year":"2023","unstructured":"Liu, H. et al. Functional connectivity of the amygdala and the antidepressant and antisuicidal effects of repeated ketamine infusions in major depressive disorder. Front. Neurosci. 17, 1123797 (2023).","journal-title":"Front. Neurosci."},{"key":"1509_CR127","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1093\/ijnp\/pyaa056","volume":"23","author":"M-H Chen","year":"2020","unstructured":"Chen, M.-H. et al. Functional dysconnectivity of frontal cortex to striatum predicts ketamine infusion response in treatment-resistant depression. Int. J. Neuropsychopharmacol. 23, 791\u2013798 (2020).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"1509_CR128","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.jad.2024.04.086","volume":"356","author":"S Wong","year":"2024","unstructured":"Wong, S. et al. Effects of anhedonia on health-related quality of life and functional outcomes in major depressive disorder: a systematic review and meta-analysis. J. Affect. Disord. 356, 684\u2013698 (2024).","journal-title":"J. Affect. Disord."},{"key":"1509_CR129","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1124\/jpet.102.046433","volume":"305","author":"SD Mague","year":"2003","unstructured":"Mague, S. D. et al. Antidepressant-like effects of \u03ba-opioid receptor antagonists in the forced swim test in rats. J. Pharmacol. Exp. Ther. 305, 323\u2013330 (2003).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1509_CR130","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jad.2024.07.030","volume":"362","author":"S Wong","year":"2024","unstructured":"Wong, S. et al. Preclinical and clinical efficacy of kappa opioid receptor antagonists for depression: a systematic review. J. Affect. Disord. 362, 816\u2013827 (2024).","journal-title":"J. Affect. Disord."},{"key":"1509_CR131","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/s41591-020-0806-7","volume":"26","author":"AD Krystal","year":"2020","unstructured":"Krystal, A. D. et al. A randomized proof-of-mechanism trial applying the \u2018fast-fail\u2019 approach to evaluating \u03ba-opioid antagonism as a treatment for anhedonia. Nat. Med. 26, 760\u2013768 (2020).","journal-title":"Nat. Med."},{"key":"1509_CR132","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/14728214.2024.2345645","volume":"29","author":"E Hampsey","year":"2024","unstructured":"Hampsey, E., Jelen, L. & Young, A. H. Aticaprant: (a \u03ba-opioid receptor antagonist) for major depressive disorder. Expert Opin. Emerg. Drugs 29, 193\u2013204 (2024).","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"1509_CR133","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s00406-024-01851-7","volume":"275","author":"K Demyttenaere","year":"2025","unstructured":"Demyttenaere, K. Aticaprant, a kappa opioid receptor antagonist, and the recovered \u2018interest and pleasure\u2019 in the concept of major depressive disorder. Eur. Arch. Psychiatry Clin. Neurosci. 275,\u00a01593\u20131597\u00a0(2025).","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"1509_CR134","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/s41386-024-01862-x","volume":"49","author":"ME Schmidt","year":"2024","unstructured":"Schmidt, M. E. et al. Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI\/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study. Neuropsychopharmacology 49, 1437\u20131447 (2024).","journal-title":"Neuropsychopharmacology"},{"key":"1509_CR135","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.biopsych.2005.09.018","volume":"59","author":"EJ Nestler","year":"2006","unstructured":"Nestler, E. J. & Carlezon, W. A. The mesolimbic dopamine reward circuit in depression. Biol. Psychiatry 59, 1151\u20131159 (2006).","journal-title":"Biol. Psychiatry"},{"key":"1509_CR136","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/da.22500","volume":"33","author":"WA Carlezon","year":"2016","unstructured":"Carlezon, W. A. & Krystal, A. D. Kappa-opioid antagonists for psychiatric disorders: from bench to clinical trials. Depress. Anxiety 33, 895\u2013906 (2016).","journal-title":"Depress. Anxiety"},{"key":"1509_CR137","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1038\/s41386-020-0738-4","volume":"45","author":"DA Pizzagalli","year":"2020","unstructured":"Pizzagalli, D. A. et al. Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS). Neuropsychopharmacology 45, 1656\u20131663 (2020).","journal-title":"Neuropsychopharmacology"},{"key":"1509_CR138","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/17425255.2018.1459564","volume":"14","author":"R-M Ragguett","year":"2018","unstructured":"Ragguett, R.-M., Rong, C., Rosenblat, J. D., Ho, R. C. & McIntyre, R. S. Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder. Expert Opin. Drug Metab. Toxicol. 14, 475\u2013482 (2018).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"1509_CR139","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05455684 (2025)."},{"key":"1509_CR140","unstructured":"Popova V. et al. (Poster Presentation) Results from the phase 3, double-blind, placebo-controlled VENTURA-1 and -2 studies of aticaprant, Adjunctive to Antidepressants, in Adults With Major Depressive Disorder with moderate-to-severe anhedonia. in American Society of Clinical Psychopharmacology (2025)."},{"key":"1509_CR141","unstructured":"Johnson & Johnson statement on VENTURA program. Johnson & Johnson https:\/\/www.jnj.com\/media-center\/press-releases\/johnson-johnson-statement-on-ventura-program (2025)."},{"key":"1509_CR142","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.biopsych.2024.02.031","volume":"95","author":"S Mathew","year":"2024","unstructured":"Mathew, S. et al. Navacaprant, a novel kappa opioid receptor antagonist for major depressive disorder: a randomized placebo-controlled phase 2 trial. Biol. Psychiatry 95, S10 (2024).","journal-title":"Biol. Psychiatry"},{"key":"1509_CR143","unstructured":"Neumora Therapeutics reports data from KOASTAL-1 study of navacaprant in major depressive disorder. GlobeNewswire https:\/\/www.globenewswire.com\/news-release\/2025\/01\/02\/3003449\/0\/en\/Neumora-Therapeutics-Reports-Data-from-KOASTAL-1-Study-of-Navacaprant-in-Major-Depressive-Disorder.html (2025)."},{"key":"1509_CR144","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/acps.13055","volume":"140","author":"A Tundo","year":"2019","unstructured":"Tundo, A., Filippis, R. & De Crescenzo, F. Pramipexole in the treatment of unipolar and bipolar depression. A systematic review and meta-analysis. Acta Psychiatr. Scand. 140, 116\u2013125 (2019).","journal-title":"Acta Psychiatr. Scand."},{"key":"1509_CR145","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jamapsychiatry.2020.2139","volume":"77","author":"DC Halahakoon","year":"2020","unstructured":"Halahakoon, D. C. et al. Reward-processing behavior in depressed participants relative to healthy volunteers: a systematic review and meta-analysis. JAMA Psychiatry 77, 1286\u20131295 (2020).","journal-title":"JAMA Psychiatry"},{"key":"1509_CR146","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S2215-0366(25)00194-4","volume":"12","author":"M Browning","year":"2025","unstructured":"Browning, M. et al. Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression: a placebo-controlled, double-blind, randomised trial in the UK. Lancet Psychiatry 12, 579\u2013589 (2025).","journal-title":"Lancet Psychiatry"},{"key":"1509_CR147","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1176\/appi.prcp.20210042","volume":"4","author":"F Ventorp","year":"2022","unstructured":"Ventorp, F. et al. Preliminary evidence of efficacy and target engagement of pramipexole in anhedonic depression. Psychiatr. Res. Clin. Pract. 4, 42\u201347 (2022).","journal-title":"Psychiatr. Res. Clin. Pract."},{"key":"1509_CR148","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.cell.2007.09.018","volume":"131","author":"V Krishnan","year":"2007","unstructured":"Krishnan, V. et al. Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell 131, 391\u2013404 (2007).","journal-title":"Cell"},{"key":"1509_CR149","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11671","volume":"7","author":"AK Friedman","year":"2016","unstructured":"Friedman, A. K. et al. KCNQ channel openers reverse depressive symptoms via an active resilience mechanism. Nat. Commun. 7, 11671 (2016).","journal-title":"Nat. Commun."},{"key":"1509_CR150","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40263-021-00885-y","volume":"36","author":"S Costi","year":"2022","unstructured":"Costi, S., Han, M.-H. & Murrough, J. W. The potential of KCNQ potassium channel openers as novel antidepressants. CNS Drugs 36, 207\u2013216 (2022).","journal-title":"CNS Drugs"},{"key":"1509_CR151","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jad.2024.05.067","volume":"359","author":"S Meshkat","year":"2024","unstructured":"Meshkat, S. et al. The role of KCNQ channel activators in management of major depressive disorder. J. Affect. Disord. 359, 364\u2013372 (2024).","journal-title":"J. Affect. Disord."},{"key":"1509_CR152","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/s41380-018-0283-2","volume":"25","author":"A Tan","year":"2020","unstructured":"Tan, A. et al. Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder. Mol. Psychiatry 25, 1323\u20131333 (2020).","journal-title":"Mol. Psychiatry"},{"key":"1509_CR153","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.biopsych.2025.02.897","volume":"98","author":"A Chowdhury","year":"2025","unstructured":"Chowdhury, A. et al. Effects of the KCNQ (Kv7) channel opener ezogabine on resting-state functional connectivity of striatal brain reward regions, depression, and anhedonia in major depressive disorder: results from a randomized controlled trial. Biol. Psychiatry 98, 568\u2013577 (2025).","journal-title":"Biol. Psychiatry"},{"key":"1509_CR154","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06419608 (2025)."},{"key":"1509_CR155","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06419582 (2024)."},{"key":"1509_CR156","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06775379 (2025)."},{"key":"1509_CR157","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41582-022-00635-8","volume":"18","author":"KJ Ressler","year":"2022","unstructured":"Ressler, K. J. et al. Post-traumatic stress disorder: clinical and translational neuroscience from cells to circuits. Nat. Rev. Neurol. 18, 273\u2013288 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"1509_CR158","unstructured":"HMNC Brain Health announces phase 2 results from OLIVE Trial in major depressive disorder (MDD) with genetically guided precision approach. GlobeNewswire https:\/\/www.globenewswire.com\/news-release\/2025\/08\/05\/3127402\/0\/en\/HMNC-Brain-Health-Announces-Phase-2-Results-from-OLIVE-Trial-in-Major-Depressive-Disorder-MDD-with-Genetically-Guided-Precision-Approach.html (2025)."},{"key":"1509_CR159","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1176\/appi.ajp.20251212","volume":"183","author":"P O\u2019Donnell","year":"2026","unstructured":"O\u2019Donnell, P., Etkin, A. & Manji, H. K. Brain neuroplasticity mechanisms in psychiatric illnesses and in the development of novel treatments. Am. J. Psychiatry\u00a0183, 98\u2013107 (2026).","journal-title":"Am. J. Psychiatry"},{"key":"1509_CR160","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/bmb\/57.1.61","volume":"57","author":"VA Vaidya","year":"2001","unstructured":"Vaidya, V. A. & Duman, R. S. Depression \u2013 emerging insights from neurobiology. Br. Med. Bull. 57, 61\u201379 (2001).","journal-title":"Br. Med. Bull."},{"key":"1509_CR161","doi-asserted-by":"publisher","first-page":"146546","DOI":"10.1016\/j.brainres.2019.146546","volume":"1727","author":"F Chen","year":"2020","unstructured":"Chen, F. et al. Hippocampal volume and cell number in depression, schizophrenia, and suicide subjects. Brain Res. 1727, 146546 (2020).","journal-title":"Brain Res."},{"key":"1509_CR162","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.biopsych.2004.08.022","volume":"56","author":"CA Stockmeier","year":"2004","unstructured":"Stockmeier, C. A. et al. Cellular changes in the postmortem hippocampus in major depression. Biol. Psychiatry 56, 640\u2013650 (2004).","journal-title":"Biol. Psychiatry"},{"key":"1509_CR163","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090980","volume":"9","author":"L-C Chang","year":"2014","unstructured":"Chang, L.-C. et al. A conserved BDNF, glutamate- and GABA-enriched gene module related to human depression identified by coexpression meta-analysis and DNA variant genome-wide association studies. PLoS ONE\u00a09, e90980 (2014).","journal-title":"PLoS ONE"},{"key":"1509_CR164","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1017\/S1461145712000016","volume":"16","author":"V Duric","year":"2013","unstructured":"Duric, V. et al. Altered expression of synapse and glutamate related genes in post-mortem hippocampus of depressed subjects. Int. J. Neuropsychopharmacol. 16, 69\u201382 (2013).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"1509_CR165","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.pnpbp.2008.10.005","volume":"33","author":"AM Feyissa","year":"2009","unstructured":"Feyissa, A. M., Chandran, A., Stockmeier, C. A. & Karolewicz, B. Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 33, 70\u201375 (2009).","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"1509_CR166","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuroscience.2015.04.057","volume":"299","author":"B Fuchsova","year":"2015","unstructured":"Fuchsova, B., Alvarez Juli\u00e1, A., Rizavi, H. S., Frasch, A. C. & Pandey, G. N. Altered expression of neuroplasticity-related genes in the brain of depressed suicides. Neuroscience 299, 1\u201317 (2015).","journal-title":"Neuroscience"},{"key":"1509_CR167","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1038\/nm.2886","volume":"18","author":"HJ Kang","year":"2012","unstructured":"Kang, H. J. et al. Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. Nat. Med. 18, 1413\u20131417 (2012).","journal-title":"Nat. Med."},{"key":"1509_CR168","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-0842-6","volume":"10","author":"L Schmaal","year":"2020","unstructured":"Schmaal, L. et al. ENIGMA MDD: seven years of global neuroimaging studies of major depression through worldwide data sharing. Transl. Psychiatry 10, 172 (2020).","journal-title":"Transl. Psychiatry"},{"key":"1509_CR169","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1080\/15622975.2016.1208840","volume":"19","author":"R Colle","year":"2018","unstructured":"Colle, R. et al. Smaller hippocampal volumes predict lower antidepressant response\/remission rates in depressed patients: a meta-analysis. World J. Biol. Psychiatry 19, 360\u2013367 (2018).","journal-title":"World J. Biol. Psychiatry"},{"key":"1509_CR170","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1139\/jpn.100002","volume":"35","author":"NV Malykhin","year":"2010","unstructured":"Malykhin, N. V., Carter, R., Seres, P. & Coupland, N. J. Structural changes in the hippocampus in major depressive disorder: contributions of disease and treatment. J. Psychiatry Neurosci. 35, 337\u2013343 (2010).","journal-title":"J. Psychiatry Neurosci."},{"key":"1509_CR171","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyv037","volume":"18","author":"JL Phillips","year":"2015","unstructured":"Phillips, J. L., Batten, L. A., Tremblay, P., Aldosary, F. & Blier, P. A. Prospective, longitudinal study of the effect of remission on cortical thickness and hippocampal volume in patients with treatment-resistant depression. Int. J. Neuropsychopharmacol. 18, pyv037 (2015).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"1509_CR172","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1080\/23279095.2015.1113536","volume":"24","author":"J-M Saury","year":"2017","unstructured":"Saury, J.-M. & Emanuelson, I. Neuropsychological assessment of hippocampal integrity. Appl. Neuropsychol. Adult 24, 140\u2013151 (2017).","journal-title":"Appl. Neuropsychol. Adult"},{"key":"1509_CR173","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S0896-6273(02)00830-9","volume":"35","author":"N Burgess","year":"2002","unstructured":"Burgess, N., Maguire, E. A. & O\u2019Keefe, J. The human hippocampus and spatial and episodic memory. Neuron 35, 625\u2013641 (2002).","journal-title":"Neuron"},{"key":"1509_CR174","doi-asserted-by":"publisher","first-page":"12085","DOI":"10.1073\/pnas.96.21.12085","volume":"96","author":"T Grunwald","year":"1999","unstructured":"Grunwald, T. et al. Evidence relating human verbal memory to hippocampal N-methyl-d-aspartate receptors. Proc. Natl Acad. Sci. USA 96, 12085\u201312089 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1509_CR175","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1017\/S0033291712002085","volume":"43","author":"E Bora","year":"2013","unstructured":"Bora, E., Harrison, B. J., Y\u00fccel, M. & Pantelis, C. Cognitive impairment in euthymic major depressive disorder: a meta-analysis. Psychol. Med. 43, 2017\u20132026 (2013).","journal-title":"Psychol. Med."},{"key":"1509_CR176","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1001\/jamapsychiatry.2023.0716","volume":"80","author":"B Cullen","year":"2023","unstructured":"Cullen, B. et al. Cognitive function in people with familial risk of depression. JAMA Psychiatry 80, 610 (2023).","journal-title":"JAMA Psychiatry"},{"key":"1509_CR177","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jad.2020.07.036","volume":"276","author":"WL Parkinson","year":"2020","unstructured":"Parkinson, W. L., Rehman, Y., Rathbone, M. & Upadhye, S. Performances on individual neurocognitive tests by people experiencing a current major depression episode: a systematic review and meta-analysis. J. Affect. Disord. 276, 249\u2013259 (2020).","journal-title":"J. Affect. Disord."},{"key":"1509_CR178","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jad.2011.10.023","volume":"140","author":"RSC Lee","year":"2012","unstructured":"Lee, R. S. C., Hermens, D. F., Porter, M. A. & Redoblado-Hodge, M. A. A meta-analysis of cognitive deficits in first-episode major depressive disorder. J. Affect. Disord. 140, 113\u2013124 (2012).","journal-title":"J. Affect. Disord."},{"key":"1509_CR179","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00787-014-0559-2","volume":"24","author":"S Wagner","year":"2015","unstructured":"Wagner, S., M\u00fcller, C., Helmreich, I., Huss, M. & Tadi\u0107, A. A meta-analysis of cognitive functions in children and adolescents with major depressive disorder. Eur. Child Adolesc. Psychiatry 24, 5\u201319 (2015).","journal-title":"Eur. Child Adolesc. Psychiatry"},{"key":"1509_CR180","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.18411","volume":"6","author":"LM Hack","year":"2023","unstructured":"Hack, L. M. et al. A cognitive biotype of depression and symptoms, behavior measures, neural circuits, and differential treatment outcomes: a prespecified secondary analysis of a randomized clinical trial. JAMA Netw. Open 6, e2318411 (2023).","journal-title":"JAMA Netw. Open"},{"key":"1509_CR181","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1017\/S003329171800034X","volume":"48","author":"S Pu","year":"2018","unstructured":"Pu, S., Noda, T., Setoyama, S. & Nakagome, K. Empirical evidence for discrete neurocognitive subgroups in patients with non-psychotic major depressive disorder: clinical implications. Psychol. Med. 48, 2717\u20132729 (2018).","journal-title":"Psychol. Med."},{"key":"1509_CR182","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/da.22063","volume":"30","author":"RS McIntyre","year":"2013","unstructured":"McIntyre, R. S. et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress. Anxiety 30, 515\u2013527 (2013).","journal-title":"Depress. Anxiety"},{"key":"1509_CR183","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/YCO.0000000000000221","volume":"29","author":"RS McIntyre","year":"2016","unstructured":"McIntyre, R. S. & Lee, Y. Cognition in major depressive disorder: a \u2018systemically important functional index\u2019 (SIFI). Curr. Opin. Psychiatry 29, 48\u201355 (2016).","journal-title":"Curr. Opin. Psychiatry"},{"key":"1509_CR184","doi-asserted-by":"publisher","first-page":"1","DOI":"10.9758\/cpn.2016.14.1.1","volume":"14","author":"YS Woo","year":"2016","unstructured":"Woo, Y. S., Rosenblat, J. D., Kakar, R., Bahk, W.-M. & McIntyre, R. S. Cognitive deficits as a mediator of poor occupational function in remitted major depressive disorder patients. Clin. Psychopharmacol. Neurosci. 14, 1\u201316 (2016).","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"1509_CR185","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1017\/S1092852918001207","volume":"24","author":"Z Pan","year":"2019","unstructured":"Pan, Z. et al. Cognitive impairment in major depressive disorder. CNS Spectr. 24, 22\u201329 (2019).","journal-title":"CNS Spectr."},{"key":"1509_CR186","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101927","volume":"58","author":"A Sankar","year":"2023","unstructured":"Sankar, A. et al. Association of neurocognitive function with psychiatric hospitalization and socio-demographic conditions in individuals with bipolar and major depressive disorders. eClinicalMedicine 58, 101927 (2023).","journal-title":"eClinicalMedicine"},{"key":"1509_CR187","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.4088\/JCP.v69n0712","volume":"69","author":"CT Gualtieri","year":"2008","unstructured":"Gualtieri, C. T. & Morgan, D. W. The frequency of cognitive impairment in patients with anxiety, depression, and bipolar disorder: an unaccounted source of variance in clinical trials. J. Clin. Psychiatry 69, 1122\u20131130 (2008).","journal-title":"J. Clin. Psychiatry"},{"key":"1509_CR188","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41386-024-01913-3","volume":"50","author":"RH Asch","year":"2025","unstructured":"Asch, R. H., Abdallah, C. G., Carson, R. E. & Esterlis, I. Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression. Neuropsychopharmacology 50, 153\u2013163 (2025).","journal-title":"Neuropsychopharmacology"},{"key":"1509_CR189","doi-asserted-by":"publisher","DOI":"10.1093\/cercor\/bhad515","volume":"34","author":"N Kaneko","year":"2024","unstructured":"Kaneko, N. et al. Neuroplasticity of the left dorsolateral prefrontal cortex in patients with treatment-resistant depression as indexed with paired associative stimulation: a TMS\u2013EEG study. Cereb. Cortex 34, bhad515 (2024).","journal-title":"Cereb. Cortex"},{"key":"1509_CR190","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41386-024-01947-7","volume":"50","author":"MP Herzberg","year":"2025","unstructured":"Herzberg, M. P., Nielsen, A. N., Luby, J. & Sylvester, C. M. Measuring neuroplasticity in human development: the potential to inform the type and timing of mental health interventions. Neuropsychopharmacology 50, 124\u2013136 (2025).","journal-title":"Neuropsychopharmacology"},{"key":"1509_CR191","unstructured":"Neurocrine Biosciences reports positive phase 2 data for NBI-1065845 in adults with major depressive disorder. PR Newswire https:\/\/www.prnewswire.com\/news-releases\/neurocrine-biosciences-reports-positive-phase-2-data-for-nbi-1065845-in-adults-with-major-depressive-disorder-302123889.html (2024)."},{"key":"1509_CR192","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06547489 (2026)."},{"key":"1509_CR193","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/01.pra.0000462606.17725.93","volume":"21","author":"S Preskorn","year":"2015","unstructured":"Preskorn, S. et al. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J. Psychiatr. Pract. 21, 140\u2013149 (2015).","journal-title":"J. Psychiatr. Pract."},{"key":"1509_CR194","unstructured":"Allergan announces phase 3 results for rapastinel as an adjunctive treatment of major depressive disorder (MDD). PR Newswire https:\/\/www.prnewswire.com\/news-releases\/allergan-announces-phase-3-results-for-rapastinel-as-an-adjunctive-treatment-of-major-depressive-disorder-mdd-300808044.html (2019)."},{"key":"1509_CR195","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05066672 (2023)."},{"key":"1509_CR196","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-40693-5","volume":"9","author":"S Sengupta","year":"2019","unstructured":"Sengupta, S. et al. Discovery of NV-5138, the first selective Brain mTORC1 activator. Sci. Rep. 9, 4107 (2019).","journal-title":"Sci. Rep."},{"key":"1509_CR197","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.biopsych.2023.11.016","volume":"95","author":"SMDD Fitzsimmons","year":"2024","unstructured":"Fitzsimmons, S. M. D. D., Oostra, E., Postma, T. S., Van Der Werf, Y. D. & Van Den Heuvel, O. A. Repetitive transcranial magnetic stimulation\u2013induced neuroplasticity and the treatment of psychiatric disorders: state of the evidence and future opportunities. Biol. Psychiatry 95, 592\u2013600 (2024).","journal-title":"Biol. Psychiatry"},{"key":"1509_CR198","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1001\/jamapsychiatry.2020.3794","volume":"78","author":"RFH Cash","year":"2021","unstructured":"Cash, R. F. H., Cocchi, L., Lv, J., Fitzgerald, P. B. & Zalesky, A. Functional magnetic resonance imaging\u2013guided personalization of transcranial magnetic stimulation treatment for depression. JAMA Psychiatry 78, 337 (2021).","journal-title":"JAMA Psychiatry"},{"key":"1509_CR199","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41583-024-00876-0","volume":"26","author":"C Liao","year":"2025","unstructured":"Liao, C., Dua, A. N., Wojtasiewicz, C., Liston, C. & Kwan, A. C. Structural neural plasticity evoked by rapid-acting antidepressant interventions. Nat. Rev. Neurosci. 26, 101\u2013114 (2025).","journal-title":"Nat. Rev. Neurosci."},{"key":"1509_CR200","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.1016\/j.biopsych.2024.02.192","volume":"95","author":"K Rasmussen","year":"2024","unstructured":"Rasmussen, K. et al. 14. Preclinical pharmacology of DLX-001, a novel non-hallucinogenic neuroplastogen with the potential for treating neuropsychiatric diseases. Biol. Psychiatry 95, S80 (2024).","journal-title":"Biol. Psychiatry"},{"key":"1509_CR201","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.neuropharm.2018.10.038","volume":"144","author":"Y Liu","year":"2019","unstructured":"Liu, Y. et al. Enhancement of synaptic plasticity and reversal of impairments in motor and cognitive functions in a mouse model of Angelman Syndrome by a small neurogenic molecule, NSI-189. Neuropharmacology 144, 337\u2013344 (2019).","journal-title":"Neuropharmacology"},{"key":"1509_CR202","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1080\/13543784.2017.1324847","volume":"26","author":"RS McIntyre","year":"2017","unstructured":"McIntyre, R. S., Johe, K., Rong, C. & Lee, Y. The neurogenic compound, NSI-189 phosphate: a novel multi-domain treatment capable of pro-cognitive and antidepressant effects. Expert Opin. Investig. Drugs 26, 767\u2013770 (2017).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"1509_CR203","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06656416 (2024)."},{"key":"1509_CR204","doi-asserted-by":"publisher","first-page":"S184","DOI":"10.1016\/j.biopsych.2024.02.441","volume":"95","author":"J Jordan","year":"2024","unstructured":"Jordan, J. et al. 206. Identification and prospective replication of a cognitive biomarker for predicting the antidepressant effect of ALTO-100, a novel pro-plasticity drug candidate, in patients with major depression: results from a large phase 2a study. Biol. Psychiatry 95, S184 (2024).","journal-title":"Biol. Psychiatry"},{"key":"1509_CR205","unstructured":"Alto Neuroscience reports third quarter 2024 financial results and recent business highlights. Alto Neuroscience https:\/\/investors.altoneuroscience.com\/news\/news-details\/2024\/Alto-Neuroscience-Reports-Third-Quarter-2024-Financial-Results-and-Recent-Business-Highlights\/default.aspx (2024)."},{"key":"1509_CR206","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1007\/s10803-019-03948-8","volume":"50","author":"E Bizzell","year":"2020","unstructured":"Bizzell, E., Ross, J., Rosenthal, C., Dumont, R. & Schaaf, R. Sensory features as a marker of autism spectrum disorders. J. Autism Dev. Disord. 50, 2240\u20132246 (2020).","journal-title":"J. Autism Dev. Disord."},{"key":"1509_CR207","doi-asserted-by":"publisher","first-page":"595","DOI":"10.5014\/ajot.2012.004523","volume":"66","author":"SJ Lane","year":"2012","unstructured":"Lane, S. J., Reynolds, S. & Dumenci, L. Sensory overresponsivity and anxiety in typically developing children and children with autism and attention deficit hyperactivity disorder: cause or coexistence? Am. J. Occup. Ther. 66, 595\u2013603 (2012).","journal-title":"Am. J. Occup. Ther."},{"key":"1509_CR208","doi-asserted-by":"crossref","unstructured":"Hudac, C. M. & Webb, S. J. in Neurophysiologic Biomarkers in Neuropsychiatric Disorders: Etiologic and Treatment Considerations (eds Javitt, D. C. & McPartland, J. C.) 545\u2013576 (Springer, 2024).","DOI":"10.1007\/978-3-031-69491-2_19"},{"key":"1509_CR209","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/jamapsychiatry.2022.1717","volume":"79","author":"E Hollander","year":"2022","unstructured":"Hollander, E. et al. Balovaptan vs placebo for social communication in childhood autism spectrum disorder: a randomized clinical trial. JAMA Psychiatry 79, 760\u2013769 (2022).","journal-title":"JAMA Psychiatry"},{"key":"1509_CR210","first-page":"767","volume":"6","author":"ZJ Williams","year":"2021","unstructured":"Williams, Z. J., Abdelmessih, P. G., Key, A. P. & Woynaroski, T. G. Cortical auditory processing of simple stimuli is altered in autism: a meta-analysis of auditory evoked responses. Biol. Psychiatry Cogn. Neurosci. Neuroimaging 6, 767\u2013781 (2021).","journal-title":"Biol. Psychiatry Cogn. Neurosci. Neuroimaging"},{"key":"1509_CR211","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.neubiorev.2018.01.008","volume":"87","author":"S Schwartz","year":"2018","unstructured":"Schwartz, S., Shinn-Cunningham, B. & Tager-Flusberg, H. Meta-analysis and systematic review of the literature characterizing auditory mismatch negativity in individuals with autism. Neurosci. Biobehav. Rev. 87, 106\u2013117 (2018).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"1509_CR212","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1007\/s10803-017-3426-4","volume":"48","author":"Y-L Chien","year":"2018","unstructured":"Chien, Y.-L., Hsieh, M. H. & Gau, S. S.-F. Mismatch negativity and P3a in adolescents and young adults with autism spectrum disorders: behavioral correlates and clinical implications. J. Autism Dev. Disord. 48, 1684\u20131697 (2018).","journal-title":"J. Autism Dev. Disord."},{"key":"1509_CR213","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.bandc.2018.03.004","volume":"123","author":"CM Hudac","year":"2018","unstructured":"Hudac, C. M. et al. Early enhanced processing and delayed habituation to deviance sounds in autism spectrum disorder. Brain Cogn. 123, 110\u2013119 (2018).","journal-title":"Brain Cogn."},{"key":"1509_CR214","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1162\/jocn.1996.8.6.551","volume":"8","author":"S Bentin","year":"1996","unstructured":"Bentin, S., Allison, T., Puce, A., Perez, E. & McCarthy, G. Electrophysiological studies of face perception in humans. J. Cogn. Neurosci. 8, 551\u2013565 (1996).","journal-title":"J. Cogn. Neurosci."},{"key":"1509_CR215","doi-asserted-by":"publisher","first-page":"709382","DOI":"10.3389\/fpsyt.2021.709382","volume":"12","author":"S Kala","year":"2021","unstructured":"Kala, S. et al. Brief Report: preliminary evidence of the N170 as a biomarker of response to treatment in autism spectrum disorder. Front. Psychiatry 12, 709382 (2021).","journal-title":"Front. Psychiatry"},{"key":"1509_CR216","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf8987","volume":"14","author":"L Mason","year":"2022","unstructured":"Mason, L. et al. Stratifying the autistic phenotype using electrophysiological indices of social perception. Sci. Transl Med. 14, eabf8987 (2022).","journal-title":"Sci. Transl Med."},{"key":"1509_CR217","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/s41591-021-01321-w","volume":"27","author":"EM Berry-Kravis","year":"2021","unstructured":"Berry-Kravis, E. M. et al. Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial. Nat. Med. 27, 862\u2013870 (2021).","journal-title":"Nat. Med."},{"key":"1509_CR218","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04644003 (2024)."},{"key":"1509_CR219","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.3390\/biomedicines12071430","volume":"12","author":"CA Erickson","year":"2024","unstructured":"Erickson, C. A. et al. Safety, tolerability, and EEG-based target engagement of STP1 (PDE3,4 inhibitor and NKCC1 antagonist) in a randomized clinical trial in a subgroup of patients with ASD. Biomedicines 12, 1430 (2024).","journal-title":"Biomedicines"},{"key":"1509_CR220","unstructured":"BQP qualification program cover letter. FDA https:\/\/www.fda.gov\/media\/127495\/download (2018)."},{"key":"1509_CR221","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1176\/appi.ajp.21050485","volume":"180","author":"SJ Webb","year":"2023","unstructured":"Webb, S. J. et al. The Autism Biomarkers Consortium for Clinical Trials: initial evaluation of a battery of candidate EEG biomarkers. Am. J. Psychiatry 180, 41\u201349 (2023).","journal-title":"Am. J. Psychiatry"},{"key":"1509_CR222","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fnint.2020.00016","volume":"14","author":"JC McPartland","year":"2020","unstructured":"McPartland, J. C. et al. The Autism Biomarkers Consortium for Clinical Trials (ABC-CT): scientific context, Study Design, and Progress Toward Biomarker Qualification. Front. Integr. Neurosci. 14, 16 (2020).","journal-title":"Front. Integr. Neurosci."},{"key":"1509_CR223","doi-asserted-by":"publisher","first-page":"101447","DOI":"10.1016\/j.dcn.2024.101447","volume":"69","author":"NA Fox","year":"2024","unstructured":"Fox, N. A. et al. The development and structure of the HEALthy Brain and Child Development (HBCD) Study EEG protocol. Dev. Cogn. Neurosci. 69, 101447 (2024).","journal-title":"Dev. Cogn. Neurosci."},{"key":"1509_CR224","unstructured":"Enrichment strategies for clinical trials to support determination of effectiveness of human drugs and biological products \u2014 guidance for industry. FDA https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/enrichment-strategies-clinical-trials-support-approval-human-drugs-and-biological-products (2019)."},{"key":"1509_CR225","unstructured":"Cancer Drug Approvals Grew from 4% of U.S. Total in the 1980s to 27% in 2010\u201318. Impact Report vol. 21 (Tufts Center for the Study of Drug Development, 2019)."},{"key":"1509_CR226","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41431-020-0589-9","volume":"28","author":"VM Pravata","year":"2020","unstructured":"Pravata, V. M. et al. An intellectual disability syndrome with single-nucleotide variants in O-GlcNAc transferase. Eur. J. Hum. Genet. 28, 706\u2013714 (2020).","journal-title":"Eur. J. Hum. Genet."},{"key":"1509_CR227","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.clinph.2020.10.017","volume":"132","author":"CL Roelofs","year":"2021","unstructured":"Roelofs, C. L. et al. Individual alpha frequency proximity associated with repetitive transcranial magnetic stimulation outcome: an independent replication study from the ICON-DB consortium. Clin. Neurophysiol. 132, 643\u2013649 (2021).","journal-title":"Clin. Neurophysiol."},{"key":"1509_CR228","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3389\/fncir.2018.00037","volume":"12","author":"BR Ferguson","year":"2018","unstructured":"Ferguson, B. R. & Gao, W.-J. PV Interneurons: critical regulators of E\/I balance for prefrontal cortex-dependent behavior and psychiatric disorders. Front. Neural Circuits 12, 37 (2018).","journal-title":"Front. Neural Circuits"},{"key":"1509_CR229","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s40473-015-0044-3","volume":"2","author":"M Heshmati","year":"2015","unstructured":"Heshmati, M. & Russo, S. J. Anhedonia and the brain reward circuitry in depression. Curr. Behav. Neurosci. Rep. 2, 146\u2013153 (2015).","journal-title":"Curr. Behav. Neurosci. Rep."},{"key":"1509_CR230","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nature11713","volume":"493","author":"D Chaudhury","year":"2013","unstructured":"Chaudhury, D. et al. Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons. Nature 493, 532\u2013536 (2013).","journal-title":"Nature"},{"key":"1509_CR231","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nature11740","volume":"493","author":"KM Tye","year":"2013","unstructured":"Tye, K. M. et al. Dopamine neurons modulate neural encoding and expression of depression-related behaviour. Nature 493, 537\u2013541 (2013).","journal-title":"Nature"},{"key":"1509_CR232","doi-asserted-by":"publisher","DOI":"10.1136\/gpsych-2021-100724","volume":"35","author":"Y-A Su","year":"2022","unstructured":"Su, Y.-A. & Si, T. Progress and challenges in research of the mechanisms of anhedonia in major depressive disorder. Gen. Psychiatry 35, e100724 (2022).","journal-title":"Gen. Psychiatry"}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01509-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01509-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01509-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T13:02:00Z","timestamp":1793278920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01509-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":232,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1509"],"URL":"https:\/\/doi.org\/10.1038\/s41573-026-01509-0","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"9 July 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.E. and P.O. receive salary from Alto Neuroscience. A.E., P.O. and H.M. hold equity in Alto Neuroscience. H.M. holds equity in Johnson & Johnson. He is Scientific Advisory Board member, Board member, strategic adviser and\/or consultant (past 5 years) for: Stanley Center, Dana Foundation, Healthy Brains Global Initiative, McLean Hospital, Foundation for OCD, Dolby Family Ventures, Vanna Health, Alto Neuroscience, Noema, Otsuka, Boehringer-Ingelheim, Sanofi, Apollo Therapeutics, Freedom Biosciences, Empyrean, Lundbeck, Psychogenics and Rapport Therapeutics. K.J.R. has performed scientific consultation for Bioxcel, Bionomics, Acer and Jazz Pharma; serves on Scientific Advisory Boards for Sage, Boehringer Ingelheim, Senseye and the Brain Research Foundation; and has received sponsored research support from Alto Neuroscience.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}